Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

AstraZeneca, Daiichi Sankyo's trastuzumab deruxtecan hits main goal of Phase II study in refractory HER2-positive metastatic breast cancer

firstwordpharmaMay 09, 2019

Tag: AstraZeneca , Daiichi Sankyo , deruxtecan

PharmaSources Customer Service